Insulin glargine vs Insulin lispro
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.
Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.
Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.
See our Terms of Use and Editorial Policy.
Insulin glargine (Lantus, Basaglar, Toujeo) and insulin lispro (Humalog, Admelog) are both injectable insulins, but they serve very different roles in diabetes management. Insulin glargine is a long-acting (basal) insulin that provides steady background coverage over 24 hours, while insulin lispro is a rapid-acting insulin used to cover meals.
Many people with type 1 diabetes use both insulins together — glargine for baseline blood sugar control and lispro before meals. In type 2 diabetes, some patients start with basal insulin alone and add mealtime insulin later if needed.
Insulin glargine vs Insulin lispro: Side-by-side comparison
| Category | Insulin glargine | Insulin lispro |
|---|---|---|
| Type | Long-acting (basal) | Rapid-acting (mealtime) |
| Brand Names | Lantus, Basaglar, Toujeo | Humalog, Admelog, Lyumjev |
| Onset of Action | 1-2 hours | 15 minutes |
| Peak Effect | No pronounced peak | 1-2 hours |
| Duration | ~24 hours | 3-5 hours |
| Typical Dosing | Once daily | Before each meal (2-3x daily) |
| Primary Role | Background blood sugar control | Post-meal blood sugar control |
Efficacy: How well does each drug work?
Insulin glargine and insulin lispro are not interchangeable — they address different aspects of blood sugar control. Glargine provides a flat, peakless insulin level over approximately 24 hours, mimicking the body's natural background insulin secretion. Clinical trials show it effectively reduces fasting blood glucose and HbA1c.
Insulin lispro acts within 15 minutes of injection and peaks in 1-2 hours, designed to handle the blood sugar spike after eating. Studies show it reduces post-meal glucose excursions more effectively than regular human insulin.
When used together in a basal-bolus regimen, this combination closely mimics natural insulin secretion and provides the tightest blood sugar control.
Side effects comparison
Hypoglycemia (low blood sugar) is the most common side effect of both insulins. However, the timing differs. Insulin glargine is associated with a lower risk of nighttime hypoglycemia compared to older basal insulins like NPH, due to its steady, peakless profile.
Insulin lispro's rapid action means hypoglycemia is more likely 1-4 hours after injection, particularly if a meal is skipped or smaller than expected. Patients must coordinate lispro injections carefully with food intake.
Both insulins can cause injection site reactions and weight gain. Long-term insulin use is associated with modest weight gain of 1-3 kg over 6-12 months.
Cost comparison
Insulin costs have been a major concern for patients. List prices for both glargine and lispro have historically been high ($300-$500 per vial), but biosimilar and authorized generic versions have increased affordability. Basaglar and Semglee are lower-cost alternatives to Lantus, while Admelog offers an alternative to Humalog.
Convenience and dosing
Insulin glargine is typically injected once daily at the same time each day. Insulin lispro is injected before each meal (usually 2-3 times daily), requiring more frequent injections and dose calculations based on carbohydrate intake.
Both are available in vials and prefilled pens. Pen devices are generally preferred for convenience and dosing accuracy.
Which is right for you?
These two insulins serve complementary roles. Insulin glargine is basal (background) insulin, while insulin lispro covers mealtimes. Your doctor will determine which you need based on your type of diabetes and blood sugar patterns.
People with type 1 diabetes almost always need both a basal and a rapid-acting insulin. People with type 2 diabetes may start with glargine alone and add lispro later if mealtime blood sugars remain elevated.
Never switch between these insulins without your doctor's guidance, as they have very different dosing, onset times, and durations.
Frequently asked questions
References
- [Observational] Lantus (insulin glargine) FDA Prescribing Information https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021081s073lbl.pdf Accessed 2026-03-01.
- [Observational] Humalog (insulin lispro) FDA Prescribing Information https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020563s115lbl.pdf Accessed 2026-03-01.
- [Observational] ADA: Insulin Basics https://diabetes.org/healthy-living/medication-treatments/insulin-other-injectables/insulin-basics Accessed 2026-03-01.
- [Observational] NIDDK: Insulin Medicines & Treatments https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments Accessed 2026-03-01.
Written and fact-checked by PrescriptionDrugs.org Editorial Team
Last updated: